前收市價 | 144.83 |
開市 | 144.01 |
買盤 | 142.62 x 100 |
賣出價 | 143.75 x 100 |
今日波幅 | 141.06 - 144.68 |
52 週波幅 | 66.03 - 161.00 |
成交量 | |
平均成交量 | 352,483 |
市值 | 8.199B |
Beta 值 (5 年,每月) | 0.51 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -9.11 |
業績公佈日 | 2024年4月25日 - 2024年4月29日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 0.29 |
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
This biotech growth stock is climbing its way up a base on its way to a buy point. The company's sales are expected to continue to soar.
Procept BioRobotics and Ascendis Pharma may not show profits but the stocks have outperformed the S&P 500 in 2024. Shares are near buy points.